
Apidra Penfill100IU/ml
Synovia Pharma PLC
Insulin Glulisine is a rapid-acting human insulin analog indicated to improve glycemic control in adults and pediatric patients with diabetes mellitus.
Insulin Glulisine is a rapid-acting human insulin analog indicated to improve glycemic control in adults and pediatric patients with diabetes mellitus.
Insulin Glulisine is not a substitute for basal insulin and must be used as part of a complete diabetes management plan individualized by a physician based on blood glucose monitoring.
The dose of Insulin Glulisine must be individualized and determined by a physician based on the patient's metabolic needs, blood glucose monitoring results, and glycemic control goals. There is no fixed universal dose.
| Indication/Route | Dosing Notes |
|---|---|
| Type 1 or Type 2 diabetes (subcutaneous injection) | Individualized mealtime dose given close to the meal, combined with basal insulin |
| Insulin pump (adults) | Individualized basal and bolus rates programmed by the prescriber; do not dilute or mix with other insulins in the pump reservoir |
| Intravenous use | Only under direct medical supervision with frequent glucose monitoring, using appropriate infusion systems |
See Use in Special Populations for information on pediatric, renal, and hepatic dosing considerations.
The most common and most serious adverse effect of Insulin Glulisine is hypoglycemia, which can be severe and, in rare cases, life-threatening.
See Precautions and Warnings and Overdose Effects for more on managing hypoglycemia related to Insulin Glulisine.
Insulin Glulisine is contraindicated in:
Disclaimer
The information provided is accurate to the best of our knowledge, but it does not replace professional medical advice. We cannot guarantee its completeness or accuracy, and the absence of specific information about a drug should not be taken as an endorsement. We are not responsible for any consequences arising from this information, so please consult a healthcare professional for any concerns or questions.